Beta-Glucuronidase Inhibition by Constituents of Mulberry Bark

Abstract

Intestinal bacterial β-glucuronidases, the key enzymes responsible for the hydrolysis of various glucuronides into free aglycone, have been recognized as key targets for treating various intestinal diseases. This study aimed to investigate the inhibitory effects and mechanisms of the Mulberry bark constituents on E. coli β-glucuronidase (EcGUS), the most abundant β-glucuronidases produced by intestinal bacteria. The results showed that the flavonoids isolated from Mulberry bark could strongly inhibit E. coli β-glucuronidase, with IC₅₀ values ranging from 1.12 µM to 10.63 µM, which were more potent than D-glucaric acid-1,4-lactone. Furthermore, the mode of inhibition of 5 flavonoids with strong E. coli β-glucuronidase inhibitory activity (IC₅₀ ≤ 5 µM) was carefully investigated by a set of kinetic assays and in silico analyses. The results demonstrated that these flavonoids were noncompetitive inhibitors against E. coli β-glucuronidase-catalyzed 4-nitrophenyl β-D-glucuronide hydrolysis, with K_i values of 0.97 µM, 2.71 µM, 3.74 µM, 3.35 µM, and 4.03 µM for morin (1), sanggenon C (2), kuwanon G (3), sanggenol A (4), and kuwanon C (5), respectively. Additionally, molecular docking simulations showed that all identified flavonoid-type E. coli β-glucuronidase inhibitors could be well-docked into E. coli β-glucuronidase at nonsubstrate binding sites, which were highly consistent with these agentsʼ noncompetitive inhibition mode. Collectively, our findings demonstrated that the flavonoids in Mulberry bark displayed strong E. coli β-glucuronidase inhibition activity, suggesting that Mulberry bark might be a promising dietary supplement for ameliorating β-glucuronidase-mediated intestinal toxicity.

Key words

Mulberry bark - Moraceae - Morus alba - intestinal bacterial - β-Glucuronidase - enzyme inhibition - flavonoid

Publication History

Received: 07 November 2020

Accepted after revision: 28 February 2021

Article published online:
17 March 2021

• References

• 1 Awolade P, Cele N, Kerru N, Gummidi L, Oluwakemi E, Singh P. Therapeutic significance of β-glucuronidase activity and its inhibitors: A review. Eur J Med Chem 2020; 187: 111921
• 2 Louis P, Hold GL, Flint HJ. The gut microbiota, bacterial metabolites, and colorectal cancer. Nat Rev Microbiol 2014; 12: 661-672
• 3 Anouar EH, Moustapha ME, Taha M, Geesi MH, Farag ZR, Rahim F, Almandil NB, Farooq RK, Nawaz M, Mosaddik A. Synthesis, molecular docking and beta-glucuronidase inhibitory potential of indole base oxadiazole derivatives. Molecules 2019; 24: 963
• 4 Kaneko A, Matsumoto T, Matsubara Y, Sekiguchi K, Koseki J, Yakabe R, Aoki K, Aiba S, Yamasaki K. Glucuronides of phytoestrogen flavonoid enhance macrophage function via conversion to aglycones by beta-glucuronidase in macrophages. Immun Inflamm Dis 2017; 5: 265-279
• 5 Oleson L, Court MH. Effect of the beta-glucuronidase inhibitor saccharolactone on glucuronidation by human tissue microsomes and recombinant UDP-glucuronosyltransferases. J Pharm Pharmacol 2008; 60: 1175-1182
• 6 Chamseddine AN, Ducreux M, Armand JP, Paoletti X, Satar T, Paci A, Mir O. Intestinal bacterial beta-glucuronidase as a possible predictive biomarker of irinotecan-induced diarrhea severity. Pharmacol Ther 2019; 199: 1-15
• 7 Roberts AB, Wallace BD, Venkatesh MK, Mani S, Redinbo MR. Molecular insights into microbial beta-glucuronidase inhibition to abrogate CPT-11 toxicity. Mol Pharmacol 2013; 84: 208-217
• 8 Swami U, Goel S, Mani S. Therapeutic targeting of CPT-11 induced diarrhea a case for prophylaxis. Curr Drug Targets 2013; 14: 777-797
• 9 Kim DH, Jin YH. Intestinal bacterial β-glucuronidase activity of patients with colon cancer. Arch Pharm Res 2001; 24: 564
• 10 Kong R, Liu T, Zhu X, Ahmad S, Williams AL, Phan AT, Zhao H, Scott JE, Yeh LA, Wong ST. Old drug new use-amoxapine and its metabolites as potent bacterial beta-glucuronidase inhibitors for alleviating cancer drug toxicity. Clin Cancer Res 2014; 20: 3521-3530
• 11 Salar U, Taha M, Ismail NH, Khan KM, Imran S, Perveen S, Wadood A, Riaz M. Thiadiazole derivatives as new class of β-glucuronidase inhibitors. Bioorg Med Chem 2016; 24: 1909-1918
• 12 Wei B, Wang PP, Yan ZX, Yan R. Characteristics and molecular determinants of a highly selective and efficient glycyrrhizin-hydrolyzing beta-glucuronidase from Staphylococcus pasteuri 3I10. Appl Microbiol Biotechnol 2018; 102: 9193-9205
• 13 Wallace BD, Roberts AB, Pollet RM, Ingle JD, Biernat KA, Pellock SJ, Venkatesh MK, Guthrie L, OʼNeal SK, Robinson SJ, Dollinger M, Figueroa E, McShane SR, Cohen RD, Jin J, Frye SV, Zamboni WC, Pepe-Ranney C, Mani S, Kelly L, Redinbo MR. Structure and inhibition of microbiome beta-glucuronidases essential to the alleviation of cancer drug toxicity. Chem Biol 2015; 22: 1238-1249
• 14 Wallace BD, Wang H, Lane KT, Scott JE, Orans J, Koo JS, Venkatesh M, Jobin C, Yeh LA, Mani S, Redinbo MR. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science 2010; 330: 831-835
• 15 Naz H, Islam A, Waheed A, Sly WS, Ahmad F, Hassan I. Human β-Glucuronidase: structure, function, and application in enzyme replacement therapy. Rejuvenation Res 2013; 16: 352-363
• 16 Cheng KW, Tseng CH, Yang CN, Tzeng CC, Cheng TC, Leu YL, Chuang YC, Wang JY, Lu YC, Chen YL, Cheng TL. Specific inhibition of bacterial beta-glucuronidase by pyrazolo[4, 3-c]quinoline derivatives via a pH-dependent manner to suppress chemotherapy-induced intestinal toxicity. J Med Chem 2017; 60: 9222-9238
• 17 Saitta KS, Zhang C, Lee KK, Fujimoto K, Redinbo MR, Boelsterli UA. Bacterial beta-glucuronidase inhibition protects mice against enteropathy induced by indomethacin, ketoprofen or diclofenac: mode of action and pharmacokinetics. Xenobiotica 2014; 44: 28-35
• 18 Pellock SJ, Creekmore BC, Walton WG, Mehta N, Biernat KA, Cesmat AP, Ariyarathna Y, Dunn ZD, Li B, Jin J, James LI, Redinbo MR. Gut microbial beta-glucuronidase inhibition via catalytic cycle interception. ACS Cent Sci 2018; 4: 868-879
• 19 Ahmad S, Hughes MA, Yeh LA, Scott JE. Potential repurposing of known drugs as potent bacterial beta-glucuronidase inhibitors. J Biomol Screen 2012; 17: 957-965
• 20 Weng ZM, Wang P, Ge GB, Dai ZR, Wu DC, Zou LW, Dou TY, Zhang TY, Yang L, Hou J. Structure-activity relationships of flavonoids as natural inhibitors against E. coli beta-glucuronidase. Food Chem Toxicol 2017; 109: 975-983
• 21 Vuorelaa P, Leinonenb M, Saikkuc P, Tammelaa P, Rauhad JP, Wennberge T, Vuorela H. Natural products in the process of finding new drug candidates. Curr Med Chem 2004; 11: 1375-1389
• 22 Lu QY, Zhang L, Eibl G, Go VL. Overestimation of flavonoid aglycones as a result of the exvivo deconjugation of glucuronides by the tissue beta-glucuronidase. J Pharm Biomed Anal 2014; 88: 364-369
• 23 Kang KB, Lee DY, Kim TB, Kim SH, Kim H, Kim J, Sung SH. Prediction of tyrosinase inhibitory activities of Morus alba root bark extracts from HPLC fingerprints. Microchem J 2013; 110: 731-738
• 24 Ha MT, Seong SH, Nguyen TD, Cho WK, Ah KJ, Ma JY, Woo MH, Choi JS, Min BS. Chalcone derivatives from the root bark of Morus alba L. act as inhibitors of PTP1B and alpha-glucosidase. Phytochemistry 2018; 155: 114-125
• 25 Tallarida RJ. Revisiting the isobole and related quantitative methods for assessing drug synergism. J Pharmacol Exp Ther 2012; 342: 2-8
• 26 Ervin SM, Hanley RP, Lim L, Walton WG, Pearce KH, Bhatt AP, James LI, Redinbo MR. Targeting regorafenib-induced toxicity through inhibition of gut microbial beta-glucuronidases. ACS Chem Biol 2019; 14: 2737-2744
• 27 Ahmad S, Hughes MA, Lane KT, Redinbo MR, Yeh LA, Scott JE. High throughput assay for discovery of bacterial beta-glucuronidase inhibitors. Curr Chem Genomics 2011; 5: 13-20
• 28 Gloux K, Anba-Mondoloni J. Unique beta-glucuronidase locus in gut microbiomes of Crohnʼs disease patients and unaffected first-degree relatives. PLoS One 2016; 11: e0148291
• 29 Carmody RN, Turnbaugh PJ. Host-microbial interactions in the metabolism of therapeutic and diet-derived xenobiotics. J Clin Invest 2014; 124: 4173-4181
• 30 Mahran E, Keusgen M, Morlock GE. New planar assay for streamlined detection and quantification of β-glucuronidase inhibitors applied to botanical extracts. Anal Chim Acta X 2020; 4: 100039
• 31 Wei B, Yang W, Yan ZX, Zhang QW, Yan R. Prenylflavonoids sanggenon C and kuwanon G from mulberry (Morus alba L.) as potent broad-spectrum bacterial β-glucuronidase inhibitors: Biological evaluation and molecular docking studies. J Funct Foods 2018; 48: 210-219
• 32 Liu YJ, Li SY, Hou J, Liu YF, Wang DD, Jiang YS, Ge GB, Liang XM, Yang L. Identification and characterization of naturally occurring inhibitors against human carboxylesterase 2 in White Mulberry Root-bark. Fitoterapia 2016; 115: 57-63
• 33 Thilakarathna SH, Rupasinghe HP. Flavonoid bioavailability and attempts for bioavailability enhancement. Nutrients 2013; 5: 3367-3387
• 34 Li J, Yang Y, Ning E, Peng Y, Zhang J. Mechanisms of poor oral bioavailability of flavonoid Morin in rats: From physicochemical to biopharmaceutical evaluations. Eur J Pharm Sci 2019; 128: 290-298
• 35 Hostetler GL, Ralston RA, Schwartz SJ. Flavones: food sources, bioavailability, metabolism, and bioactivity. Adv Nutr 2017; 8: 423-435
• 36 Yuan Q, Zhao L. The Mulberry (Morus alba L.) fruit–a review of characteristic components and health benefits. J Agric Food Chem 2017; 65: 10383-10394
• 37 Xin H, Qi XY, Wu JJ, Wang XX, Li Y, Hong JY, He W, Xu W, Ge GB, Yang L. Assessment of the inhibition potential of Licochalcone A against human UDP-glucuronosyltransferases. Food Chem Toxicol 2016; 90: 112-122
• 38 Wei LH, Chen TR, Fang HB, Jin Q, Zhang SJ, Hou J, Yu Y, Dou TY, Cao YF, Guo WZ, Ge GB. Natural constituents of St. Johnʼs Wort inhibit the proteolytic activity of human thrombin. Int J Biol Macromol 2019; 134: 622-630